Search
Oral Polio Vaccine
go.drugbank.com/drugs/DB15864InvestigationalThe polio vaccine can be either administered in the inactivated form or the oral form, although both series comprises 4 doses and is also interchangeable in administration form so long all as 4 doses are
Interferon alfa-2b
go.drugbank.com/drugs/DB00105ApprovedInvestigationalIt is used extensively as an antiviral or antineoplastic agent.
Categories: Cytochrome P-450 CYP1A2 Inhibitors, Cytochrome P-450 Enzyme InhibitorsBradanicline
go.drugbank.com/drugs/DB06090InvestigationalBradanicline belongs to a new class of drugs for the treatment of central nervous system diseases and disorders. … Bradanicline, a novel small molecule that modulates the activity of the neuronal nicotinic receptor (NNR) subtype known as alpha7(α7).
Agalsidase beta
go.drugbank.com/drugs/DB00103ApprovedInvestigationalWhile patients generally do not experience a clinically significant difference in outcomes between the two drugs, some patients may experience greater benefit with agalsidase beta.
SAR445136
go.drugbank.com/drugs/DB17708InvestigationalSAR445136 is an investigational zinc finger nuclease gene-edited cell therapy. … [A259063] It was formerly investigated for the treatment of beta-thalassemia, and it is currently being investigated for the treatment of sickle cell disease.[L46148]
Medrysone
go.drugbank.com/drugs/DB00253ApprovedMedrysone is a corticosteroid used in ophthalmology.
Categories: Corticosteroid Hormone Receptor Agonists, P-glycoprotein substratesEGT-301
go.drugbank.com/drugs/DB17649ExperimentalEGT-301 is a gene therapy being investigated for Hunter Syndrome. … It consists of an adeno-associated viral vector serotype 9 (AAV9) containing the human Iduronate-2-sulfatase (I2S) transgene designed to restore I2S functional deficiency in patients with Hunter syndrome
Coagulin-B
go.drugbank.com/drugs/DB17703ExperimentalCoagulin-B is an adeno-associated viral vector expressing human blood-coagulation Factor IX. … [A259038, A259043] It was previously investigated for the treatment of hemophilia; however, the manufacturing company discontinued the Phase I trial in 2004, halting its further development and investigation
Lubazodone
go.drugbank.com/drugs/DB09196ExperimentalLubazodone (YM-992, YM-35,995) is an arylpiperazine antidepressant which was being developed as a treatment for depression and obsessive compulsive disorder, and reached phase II clinical trials, but was … It acts as a serotonin reuptake inhibitor and 5-HT2A receptor antagonist.